BioNTech Investor Day Presentation Deck

100 iNeST | Autogene cevumeran (BNT122) Immune response correlates with delayed recurrence in adjuvant PDAC RFS from resection (n=16) RFS (%) 50- No. at risk Responder Non-responder 00 00 0 6 8 Median RFS: Not reached 8 Median RFS: 13.7 months 8 6 12 18 24 Time (months) iNeST is being developed in collaboration with Genentech. Balachandran VP, et al. ASCO Annual Meeting 2022; Poster presentation 2516. 7 5 62 2 20 30 00 ● ● Responder positive assay 1 and 2 Median follow-up: 18 months HR=0.08 (95% CI 0.01-0.40); p=0.003 = A follow-up randomization trial is being developed NUM mRNA cancer vaccines BIONTECH 106

View entire presentation